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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
To determine the diagnostic accuracy of SLNB for the detection of nodal metastases (in the investigated nodal basin) for the staging
of cutaneous invasive melanoma.
To determine the diagnostic accuracy of imaging tests for the detection of any metastasis in the primary staging of cutaneous invasive
melanoma (i.e. staging at presentation).
To determine the diagnostic accuracy of imaging tests for the detection of any metastasis in the staging of recurrence in cutaneous
invasive melanoma (i.e. re-staging prompted by findings on routine follow-up).
To determine the diagnostic accuracy of imaging tests for the detection of nodal metastases in the staging of cutaneous invasive
melanoma.
To determine the diagnostic accuracy of imaging tests for the detection of distant metastases in the staging of cutaneous invasive
melanoma.
These will be estimated separately for those undergoing primary staging and those who have experienced a disease recurrence.
Investigation of sources of heterogeneity
We will consider a range of potential sources of heterogeneity for investigation in each individual test review. These may vary between
reviews but may include the following.
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i. Population characteristics
• AJCC stage of disease
• Sentinel lymph node status (for imaging studies only)
• Clinical nodal status (for imaging studies only)
• Primary tumour site (head and neck, trunk, limb, and other)
ii. Index test characteristics
• Differences in test positivity thresholds (e.g. for SLNB, the tracer threshold for a ’hot’ versus ’cold’ node)
• Other relevant test characteristics as appropriate to the test under consideration
iii. Reference standard characteristics
• Reference standard used (histology, clinical or imaging-based follow-up; concurrent imaging-based reference standard)
iv. Study quality
• Consecutive or random sample of participants recruited
• Index test interpreted, blinded to the reference standard result
• Index test interpreted, blinded to the result of any other index test
• Presence of partial or differential verification bias (whereby only a sample of those subject to the index test are verified by the
reference test or by the same reference test, with selection dependent on the index test result)
• Use of an adequate reference standard
• Overall risk of bias
We will examine the quality and quantity of research evidence available on the effectiveness of each index test for the primary target
condition and make recommendations regarding where further research might be required.
B A C K G R O U N D
Cochrane Skin (CSG, Nottingham) in collaboration with the Test
Evaluation Research Group in the Institute of Applied Health Re-
search (TERG, Birmingham) are undertaking a series of Cochrane
Diagnostic Test Accuracy (DTA) Reviews on the diagnosis and
staging of melanoma and keratinocyte skin cancers, as part of the
National Institute for Health Research (NIHR) Cochrane System-
atic Reviews Programme. Appendix 1 shows the current content
and structure of the programme.
As several reviews for each topic area will follow similar method-
ology, we have prepared generic protocols in order to avoid dupli-
cation of effort.
This protocol concerns the evaluation of tests for the staging of
cutaneous melanoma (i.e. to determine the extent of disease in
those with an already confirmed diagnosis of melanoma), includ-
ing sentinel lymph node biopsy (SLNB) for detection of nodal
metastases and imaging tests for the detection of any metastatic
disease. A separate Cochrane protocol is available for the staging
of cutaneous squamous cell carcinoma (cSCC) (Dinnes 2017), for
the diagnosis of melanoma (Dinnes 2015a), and for the diagnosis
of keratinocyte skin cancer (Dinnes 2015b). The Background and
Methods sections of this protocol use some text that was originally
published in the protocol concerning the evaluation of tests for
the diagnosis of melanoma (Dinnes 2015a).
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Table 1 provides a glossary of terms used.
Target condition being diagnosed
Melanoma skin cancer arises from uncontrolled proliferation of
melanocytes, the epidermal cells that produce pigment or melanin.
It can occur in any organ that contains melanocytes, including
the eye and internal organs, but most commonly arises in the
skin (McLaughlin 2005). Cutaneous melanoma refers to any le-
sion with malignant melanocytes present in the deeper layers of
the skin, the dermis, and includes superficial spreading, nodular,
acral lentiginous, and lentigo maligna melanoma variants (SIGN
2003). Melanoma in situ refers to malignant melanocytes that are
contained within the epidermis and have not yet spread into the
dermis, but are at risk of progression to invasive melanoma if left
untreated (Lens 2004). It is one of the most dangerous forms of
skin cancer, with the potential to metastasise (or spread) to other
parts of the body; it accounts for only a small percentage of skin
cancer, cases but is responsible for up to 75% of skin cancer deaths
(Boring 1994).
The overall worldwide incidence of skin cancer is difficult to esti-
mate, as there is often no requirement for the more common forms
of skin cancers to be reported to cancer registries (Lomas 2012).
In 2003, the World Health Organization estimated that 132,000
melanoma skin cancers occur globally each year compared to be-
tween two and three million non-melanoma skin cancers (pri-
marily basal cell carcinoma (BCC) and cutaneous squamous cell
carcinoma (cSCC)) (WHO 2003). Estimates of the incidence of
melanoma have since increased to over 200,000 newly diagnosed
cases worldwide (2012 data) (Erdmann 2013; Ferlay 2015), with
an estimated 55,000 deaths (Ferlay 2015). In the UK, melanoma
has one of the fastest rising incidence rates of any cancer, and has
had the biggest projected increase in incidence between 2007 and
2030 (Mistry 2011). In the decade leading up to 2013, age stan-
dardised incidence increased by 46%, with 14,500 new cases in
2013 and 2459 deaths in 2014 (Cancer Research UK 2017).
The rising incidence in melanoma is thought to be primarily re-
lated to rising recreational sun exposure and tanning bed use,
and an increasingly ageing population with higher lifetime recre-
ational ultraviolet (UV) exposure (Boniol 2012; Gandini 2005),
in conjunction with possible earlier detection (Linos 2009). Risk
factors can be broadly divided into host or environmental fac-
tors. Host factors include pale skin and light hair or eye colour
(Evans 1988); older age (Geller 2002); male sex (Geller 2002);
previous skin cancer (Tucker 1985); predisposing skin lesions, e.g.
high melanocytic naevus counts (Gandini 2005), clinically atyp-
ical naevi (Gandini 2005), or large congenital naevi (Swerdlow
1995); genetically inherited skin disorders e.g. xeroderma pig-
mentosum (Lehmann 2011); and a family history of melanoma
(Gandini 2005). Environmental factors include recreational, occu-
pational, and work-related exposure to sunlight (both cumulative
and episodic burning) (Gandini 2005); artificial tanning (Boniol
2012); and immunosuppression, e.g. as seen in organ transplant
recipients or human immunodeficiency virus (HIV)-positive in-
dividuals (DePry 2011). Lower socioeconomic class may be asso-
ciated with delayed presentation and thus more advanced disease
at diagnosis (Reyes-Ortiz 2006).
The main prognostic indicators following diagnosis of cutaneous
melanoma can be divided into histological and clinical factors.
Histologically, Breslow thickness is the single most important pre-
dictor of survival, as it is a quantitative measure of tumour inva-
sion or volume, and thus propensity to metastasise (Balch 2001).
Other factors associated with poorer prognosis histologically in-
clude microscopic ulceration, mitotic rate, microscopic satellites,
regression, lymphovascular invasion, and nodular (rapidly grow-
ing) or amelanotic (lacking in melanin pigment) subtypes (Moreau
2013; Shaikh 2012). Independent of tumour thickness, prognosis
is worse in older people, males, and those with locally recurrent
lesions, regional lymph node involvement, or primary lesion loca-
tion on the scalp or neck (Zemelman 2014).
Following histological confirmation of diagnosis, the lesion is
staged according to the American Joint Committee on Cancer
(AJCC) Staging System to inform treatment strategy (Table 2 (a))
(Balch 2009). Stage 0 refers to melanoma in situ; stages I to II
localised melanoma; stage III regional metastasis (spread to the
lymph nodes, usually but not always, those nearest to the primary
tumour); and stage IV distant metastasis. A preliminary stage is
assigned based on histological evaluation (thickness of primary le-
sion, presence of ulceration or mitoses) and clinical (and some-
times radiological) assessment of the regional lymph nodes (Balch
2009) (Table 2 (b)). A pathological stage is then confirmed based
on histology of the primary lesion and of the regional lymph nodes
(if the patient has either sentinel lymph node biopsy (SLNB) or
complete lymph node dissection), and with imaging to confirm
the presence or absence of disseminated disease, where indicated.
Survival following diagnosis of melanoma is closely linked to stage
of disease. Data from the USA published in 2009, indicated a
five-year survival of 91% to 95% for stage I melanoma (Breslow
thickness ≤ 1 mm), dropping to 27% to 69% in stage III dis-
ease (Balch 2009). Disseminated melanoma to distant sites and
visceral organs has been incurable; prior to the advent of targeted
and immunotherapies, median survival was six to nine months,
with a one-year survival rate of 25%, and three-year survival of
15% (Balch 2009; Korn 2008). Between 1975 and 2010, five-
year relative survival for melanoma in the USA increased from
80% to 94%, with survival for localised, regional, and distant dis-
ease estimated at 99%, 70%, and 18%, respectively, in 2010 (Cho
2014). Overall mortality rates however, showed little change, at
2.1 deaths per 100,000 in 1975 and 2.7 per 100,000 in 2010 (Cho
2014). Increasing incidence in localised disease over the same pe-
riod (from 5.7 to 21 per 100,000) suggests that much of the ob-
served improvement in survival may be due to earlier detection and
heightened vigilance (Cho 2014). Targeted therapies for stage IV
melanoma (e.g. BRAF inhibitors) have improved survival expec-
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tation, and immunotherapies are evolving, such that, very long-
term survival is being documented (see ’Treatment of melanoma’).
Treatment of melanoma
The treatment of melanoma varies to some extent, according to the
stage of disease upon diagnosis. For primary melanoma, the main-
stay of treatment is complete lesion excision, with a safety margin
some distance from the borders of the primary tumour in order to
remove both the tumour and any malignant cells that might have
spread into the surrounding skin (Garbe 2016; Marsden 2010;
NICE 2015a; Sladden 2009). Recommended surgical margins
vary according to tumour thickness and stage of disease at presen-
tation (Garbe 2016; NICE 2015a). There is mixed evidence for
further local or regional interventions. A Cochrane Review of five
randomised controlled trials (RCTs) found no evidence for overall
survival from wider surgical margins (Sladden 2009); however, a
more recent meta-analysis of six RCTs suggested a non-statistically
significant benefit in terms of overall survival and recurrence-free
survival from wider margins (hazard ratio for overall survival 1.09,
95% confidence interval (CI) 0.98 to 1.22) and a significant bene-
fit in terms of melanoma-specific survival (hazard ratio 1.17, 95%
CI 1.03 to 1.34; P = 0.02) (Wheatley 2016). A non-systematic
review found no evidence for elective lymph node dissection (5
RCTs), prophylactic isolated limb perfusion (1 RCT), or sentinel
node biopsy followed by complete lymph node dissection (1 RCT)
having any impact on survival (Eggermont 2007). The latter con-
clusion has been supported by a large RCT showing no disease-
free survival benefit for sentinel node biopsy when combined with
selective removal of positive nodes (selective lymphadenectomy),
making its therapeutic use controversial in the absence so far of ef-
fective adjuvant therapies (Kyrgidis 2015; Morton 2014). Guide-
lines recommend SLNB only for use as a staging, rather than ther-
apeutic procedure (Garbe 2016; NICE 2015a).
For stage III melanoma, completion lymphadenectomy (removal
of all regional lymph nodes when at least one diseased node is
identified on SLNB) (or complete lymph node dissection) should
be considered only after the potential benefits and disadvantages
of the procedure have been “critically discussed” (NICE 2015a),
especially with patients with small tumour deposits (<= 1 mm di-
ameter), as no survival benefit has yet been shown (Garbe 2016).
No adjuvant radiotherapy or adjuvant systemic treatment is rec-
ommended for routine use in stage I, II or III disease in the UK
(NICE 2015a), and in many parts of Europe (Garbe 2016). Inter-
feron-alpha has been licensed as an adjuvant treatment for stage
IIB and stage III melanoma in the USA and Europe (licensed by
Food and Drug Administration (FDA) and European Medicines
Agency (EMA)) (Garbe 2016); however, a systematic review found
evidence for its effectiveness to be stronger in terms of disease-free
survival than overall survival (Mocellin 2013). The general lack of
effective adjuvant therapies had been linked to the lack of effective
drugs that have historically been available to treat advanced disease
(Eggermont 2007), but very recently, Eggermont et al reported
prolonged survival with adjuvant ipilimumab (Eggermont 2016).
For many years, dacarbazine was the only drug approved world-
wide for stage IV melanoma, with fotemustine used in some Eu-
ropean countries (Avril 2004), and interleukin (IL)-2 given in
the USA (Atkins 1999). Temozolomide has also been used, espe-
cially for people with brain metastases, because of its greater abil-
ity to pass the blood-brain barrier (Lukas 2014; Zhu 2014). This
landscape has changed dramatically with two distinct therapeutic
approaches suggesting survival benefits in metastatic melanoma:
targeting mutations in tumour cells and immunomodulation
(Chapman 2011; Hamid 2013; Hodi 2010).
The discovery of driver mutations in melanoma has allowed the
development of pharmacological inhibitors that target mutated
signal transduction in the RAS-RAF-MEK-ERK signalling path-
way, e.g. BRAF inhibitors (Chapman 2012; Villanueva 2010), and
MEK inhibitors (Dummer 2014; Larkin 2014). Three such ther-
apies are currently recommended in the UK for those with unre-
sectable or metastatic BRAF V600 mutation-positive melanoma
(around 45% of patients (Garbe 2016)): dabrafenib (NICE
2014a), vemurafenib (NICE 2012b), or trametinib in combi-
nation with dabrafenib (NICE 2016b). The limitation of these
treatments is the short median length of response due to the de-
velopment of multiple resistance mechanisms (Chapman 2012;
Villanueva 2010); however, combinations of BRAF and MEK
inhibitors show greater promise in patients with BRAF-mutant
melanoma (Robert 2015), with European guidelines recommend-
ing this approach as standard treatment, where indicated (Garbe
2016).
Immunotherapy-based approaches include ipilimumab,
nivolumab, and pembrolizumab which have been approved in the
USA and Europe (Hodi 2010), and by the National Institute for
Health and Care Excellence (NICE) in the UK, both alone (NICE
2012a; NICE 2014a; NICE 2014b; NICE 2015b; NICE 2015c),
and in combination (NICE 2016a; NICE 2016b). These have
shown high response rates, and most importantly, demonstrate
for the first time in the treatment of melanoma, the potential for
a durable clinical response (Chapman 2011; Hamid 2013; Hodi
2010; Hodi 2016; Larkin 2015; Maio 2015; Sznol 2013).
A Cochrane Review comparing the efficacy of available systemic
therapies for stage IIIC and stage IV melanoma is currently under-
way (Pasquali 2014), as are a number of further NICE appraisals
of new therapeutic agents, including binimetinib, talimogene la-
herparepvec, and temozolomide (NICE 2017).
Psychosocial interventions to improve quality of life and general
psychological distress in cancer patients following a diagnosis, are
also available; however, a Cochrane Review found considerable
variation in the evidence to support such interventions (Galway
2012).
Index test(s)
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Accurate staging of melanoma is more important than ever, partly
to avoid unnecessary treatment and associated morbidity in those
with early stage disease, and also to ensure that potentially effective
therapies are initiated in a timely manner in those with metastatic
disease who are well enough to tolerate them. The response to
treatment in these patients may be better when the volume of
disease is small, and will be better tolerated when the patient is
systemically well (i.e. with good performance status).
These reviews will evaluate a range of available tests used for
staging cutaneous melanoma. The first step towards determining
melanoma stage is taking a detailed clinical history to determine
if there are any symptoms suggesting spread of disease. This is fol-
lowed by a thorough clinical examination, including whole body
skin examination and palpation of the regional lymph nodes. In
current practice, SLNB may be considered in stage IB and stage II
melanoma for those without palpable lymph nodes. The majority
of staging in terms of imaging is undertaken in clinical stage III
and IV disease (see Clinical pathway).
Sentinel lymph node biopsy (SLNB)
SLNB allows the detection of metastatic spread to the regional
lymph node basins (clusters of lymph nodes, including axillary
(under arm), inguinal (groin), and cervical (neck), but can also
be found on the upper arm (epitrochlear), or behind the knee
(popliteal)). SLNB is usually performed by a plastic surgeon at the
same time as wide local excision of the primary melanoma (NICE
2015a). A radioactive tracer and patent blue dye are injected into
the dermis at and surrounding the primary lesion or excision
biopsy scar. The ’sentinel’ lymph nodes to which the tracer drains
are located by imaging (usually lymphoscintigraphy) and then re-
moved and examined microscopically for micrometastases (cancer
spread that cannot be seen by the naked eye) (NICE 2015a). The
presence of micrometastases directly informs pathological staging
as outlined in Table 2.
By definition, SLNB is useful only for the detection of locoregional
disease via lymphatic spread, so although imaging is used to detect
the sentinel nodes, it is not considered to be an ’imaging’ test.
Purely imaging-based tests, which can visualise larger areas of the
body, can also detect distant metastatic disease, which occurs via
lymphatic or haematogenous spread. While SLNB is restricted to
primary staging on initial confirmation of a melanoma diagnosis,
imaging can be undertaken on initial presentation of disease, on
development of recurrence, and during follow-up (Melanoma
Focus 2014). The latter use of imaging, as a monitoring test with
the aim of early detection of recurrence, is not the focus of our
reviews.
Imaging tests are undertaken and interpreted by radiologists,
with decisions about patient management following imaging or
SLNB made at multidisciplinary team meetings as discussed in
the Clinical pathway section below.
Ultrasound
Ultrasound can be used to assist the detection of diseased lymph
nodes; with those who have a positive imaging result, proceeding
to fine needle aspiration cytology (FNAC), core biopsy, or SLNB.
A 2011 systematic review identified 21 studies of ultrasound for
either primary lymph node staging or surveillance; for primary
staging sensitivity was 60% with a specificity of 97% (the number
of studies that considered staging versus surveillance is unclear)
(Xing 2011).
A 2013 systematic review of 10 studies, using both image-guided
and non-image-guided FNAC, demonstrated an overall sensitiv-
ity of 97% and a specificity of 99%, and included two studies us-
ing only ultrasound-guided FNAC (Hall 2013). No systematic re-
views of ultrasound-guided core needle biopsy in melanoma have
been identified; however, a recently published case series showed
sensitivity of 98% and specificity of 100% (Bohelay 2015).
Computed tomography (CT) (non-contrast or
contrast-enhanced)
CT scans use x-rays to take cross-sectional images of the body,
often using coronal and sagittal reformats (Bluemm 1983; van
Waes 1983). The procedure involves varying amounts of radiation
according to the area of the body to be scanned (Mahesh 2017),
and can be conducted using an intravenous contrast agent (con-
trast-enhanced) to increase the sensitivity of metastasis detection
in solid organs.
The Mohr 2009 study describes contrast-enhanced CT as the best
method of identifying intrathoracic metastases, as superior to x-
ray for detection of mediastinal and hilar adenopathy associated
with lymphatic spread, and for assessment of lesions in the bone.
CT can also be used for assessment of metastatic spread to the
brain (Goulart 2011). As melanoma is one of the top three can-
cers responsible for cerebral metastases (Cagney 2017), the accu-
racy of CT in comparison with other imaging tests needs to be
established. Overall specificity is reportedly high for detection of
regional and distant disease, but sensitivity varies from 23% to
85% for detection of lymph node metastases, and 25% to 74%
for assessment of distant spread (Xing 2011).
Magnetic resonance imaging (MRI) (non-contrast or
contrast-enhanced)
MRI scans use magnets and radiowaves rather than radiation to
generate images, which are then computer processed to produce
cross-sectional ’slices’ of the body (Ai 2012). MRI scans are more
expensive and take longer to carry out compared to CT scans
(Whaley 2016b).
We did not identify any systematic reviews of MRI for melanoma
staging from our scoping searches; however, a number of studies
have considered whole body MRI (Jouvet 2014; Mosavi 2013),
and MRI for detection of brain (Aukema 2010), or hepatic metas-
tases (Sofue 2012).
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Positron emission tomography (PET) or PET-CT
(positron emission tomography-computed
tomography)
Positron emission tomography (PET) is a nuclear medicine
technique whereby a radioactive glucose analogue (usually
fludeoxyglucose 18F (18FDG)) is administered intravenously,
which is then metabolised as part of the body’s normal function
(Lammertsma 2017). The PET scanner detects the FDG and an
image is created showing where FDG uptake is high. Tumours
take up more FDG than normal tissue due to a higher rate of
metabolism, with malignant masses generally being more ’active’
than benign ones (Oncolink 2016). PET can also be combined
with CT to provide both functional and structural information.
The use of PET in combination with CT will necessarily increase
the radiation exposure of the patient (IAEA 2016).
PET-CT is generally considered to be a more sensitive test than
CT alone (Xing 2011); however, it has not been determined
whether any increase in sensitivity confers patient benefit in
terms of changes in management, and ultimately patient out-
comes (Schroer-Gunther 2012). It may be that PET-CT has the
most added value for patients with smaller metastatic deposits
that are easier to control with stereotactic surgery (Youland 2017),
for metastases in areas that are difficult to image with CT or
other imaging modalities (Tan 2012), or those with indeterminate
metastases in areas such as the lung. Whether these assumptions
are supported by current evidence has yet to be established. The
evidence report for the NICE guideline found no evidence “to
suggest that earlier treatment of metastatic disease improves sur-
vival and therefore increased sensitivity was viewed currently as
not an important issue” (NICE 2015d).
Clinical pathway
The diagnosis of melanoma can take place in primary, sec-
ondary, and tertiary care settings, by both generalist and special-
ist healthcare providers; however, the staging of confirmed disease
takes place in secondary and tertiary care settings only (NICE
2015a). The recommendations on the management of melanoma
following diagnosis, published in the recent NICE Guideline
(NICE 2015a), and other UK guideline documents (Burkill 2014;
Marsden 2010; Melanoma Taskforce 2011), are summarised in
Figure 1, and outlined below; however, it should be noted that
practice varies across the UK.
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Figure 1. Summary of NICE guideline recommendations for the management of cutaneous melanoma
following primary diagnosis (NICE guidance 2015)
Following complete excision of the primary lesion, all patients
should undergo a full clinical examination of both the skin and re-
gional lymph nodes (NICE 2015a). Preliminary staging can then
be assigned based on the outcome of this and histopathology re-
sults for the primary lesion(s). Those with palpable lymph nodes
are automatically assigned to stage III while those with no palpable
lymph nodes are assigned a stage between 0 and IIC, according to
the thickness of the tumour (Breslow) and the presence of ulcera-
tion or mitoses (Balch 2009).
The results of all investigations carried out in the process of di-
agnosis will be discussed at a multidisciplinary team meeting
(Melanoma Taskforce 2011), where decisions regarding further
staging (i.e. the index tests of interest for this protocol) and other
investigations are made, and the results of all investigations carried
out in the process of diagnosis are discussed. This could be a local
skin multidisciplinary team, or for those with stage IIB disease and
above, a specialist skin multidisciplinary team (Marsden 2010).
These teams should include dermatologists, surgeons (including
plastic surgeons), medical and clinical oncologists, radiologists,
histopathologists, skin cancer nurse specialists, physiotherapists,
psychologists, lymphoedema services, occupational therapists, and
cosmetic camouflage advisers (Melanoma Taskforce 2011).
No further staging investigations are currently recommended for
people with thin melanomas (<= 1 mm) without ulceration or
mitoses (up to stage IA) (NICE 2015a).
Sentinel lymph node biopsy (SLNB) may be considered for those
with stage IB melanoma (<= 1 mm but with surface ulceration
or mitoses) and stage II disease (i.e. clinically node negative and
with Breslow thickness > 1 mm) (NICE 2015a), to detect any
micrometastases in the nearest draining lymph node basin. If mi-
crometastasis is detected, the stage of disease becomes stage III
and patients should be counselled about the potential advantages
and disadvantages of complete lymph node dissection (Marsden
2010). Those with clinically palpable lymph nodes or nodes found
to be diseased on imaging may also undergo complete lymph node
dissection. Stage III A, B or C is assigned according to lesion
characteristics and the presence of micro- or macrometastases (i.e.
clinically detectable nodal metastases) and the number of disease
nodes identified (Table 2).
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Available recommendations on appropriate use of imaging vary
to some extent, even within the UK (Burkill 2014; Melanoma
Focus 2014; NICE 2015a). CT is generally the imaging test of
choice; however, some centres offer high resolution ultrasound,
MRI, or PET scans in addition to, or in some cases instead of
SLNB. NICE recommend that CT staging to identify those who
may benefit from systemic therapy should be reserved for those
with stage IIC (if no SLNB has been undertaken) and stage III or
suspected stage IV disease (NICE 2015a). Imaging of the brain
should be considered only if metastatic disease outside the central
nervous system is suspected; with CT used for adults and MRI
for children and young adults aged under 25 to reduce long-term
risks of radiation (NICE 2015a).
The Melanoma Focus position paper on follow-up of high risk
melanoma in the UK recommends that at baseline (and during
follow-up) high risk patients (as defined by the local specialist
skin multidisciplinary team) should undergo CT of the chest,
abdomen, and pelvis (or total body PET-CT), plus MRI of the
head, as standard (Melanoma Focus 2014).
The Royal College of Radiologists guideline recommends that
scans should be tailored according to the site of the primary le-
sion and most likely regional lymph node basin. In general, CT
imaging of the head, chest, abdomen, and pelvis should be em-
ployed for lower limb and lower body wall lesions, with the addi-
tion of CT of the neck for upper limb, scalp, neck, and upper torso
primary tumours (Burkill 2014). MRI may be more appropriate
for imaging the central nervous system (Burkill 2014). Although
PET-CT has been suggested to have a role in imaging the lower
limbs, further evidence is required (Burkill 2014).
Patients with stage IIIB melanoma and above will also be offered
genotyping, for example, to identify BRAF mutations to allow fur-
ther planning of systemic treatment (Melanoma Taskforce 2011);
however, systemic treatment is generally only currently recom-
mended for those with stage IV disease or extensive locoregional
disease that is not amenable to surgery, according to available
NICE guidance (see ’Treatment of Melanoma’ section).
The performance of SLNB, and of particular imaging tests, may
also be a requirement for enrolment in ongoing clinical trials of
treatment.
Role of index test(s)
SLNB currently provides one method of identifying those with-
out clinically palpable lymph nodes to improve prognosis estima-
tion. Although it carries less of a burden in terms of morbidity
compared to lymph node dissection, it is still an invasive proce-
dure with a certain risk of adverse events (estimated at 5% mor-
bidity) (Marsden 2010), and has no established survival advan-
tage (Kyrgidis 2015; Morton 2014). Ultrasound with FNAC is
not sufficiently sensitive to replace SLNB but has been suggested
to have a role in fast-tracking those with positive cytology results
(micrometastases identified) to complete lymph node dissection,
while those with negative cytology may proceed to SLNB, as re-
quired (Voit 2014).
There is currently no recommended role for imaging tests in early
stage disease, but CT has been recommended as the imaging ap-
proach of choice for detection of nodal and distant spread in those
with stage III or IV disease (and for those with stage IIC if no
SLNB has been performed) (NICE 2015a). PET-CT is increas-
ingly being used; however, practice varies across the country, pri-
marily according to availability. The advantages to patient man-
agement with PET-CT are not yet known. The most appropriate
role for MRI in staging melanoma in adults, other than for central
nervous system disease, is unclear.
Alternative test(s)
A number of other tests may be used to inform patient manage-
ment following a diagnosis of melanoma.
When clinically palpable lymph nodes are identified, core needle
biopsy or FNAC of the lymph node may be undertaken to confirm
the presence of macrometastases, i.e. metastases that are palpable
(Marsden 2010). Fine needle aspiration is a fairly simple proce-
dure which allows a sample of cells to be taken from the lymph
node with a fine needle (Hall 2013), while core needle biopsy
uses a slightly larger needle with a hollow centre, allowing the re-
moval of a core of tissue with the cell structure intact (Whaley
2016a). Both procedures can be guided by simple palpation or, for
more deep-seated lesions, with image-based guidance to identify
micrometastases (requiring use of a microscope to be visualised)
(Bohelay 2015). Although the accuracy of core needle biopsy in
comparison to fine needle aspiration has been identified as a key
clinical question to be investigated, it is beyond the scope of these
reviews which focus on the detection of nonpalpable metastatic
disease.
Genetic testing of primary melanoma specimens, for BRAF mu-
tations for example, is increasingly used, particularly with the
emergence of systemic treatments for BRAF V600 mutation-pos-
itive melanoma (Chapman 2011; Chapman 2012; Larkin 2014;
Larkin 2015). A survey for the NICE guideline found 54% of
local skin multidisciplinary teams and 83% of specialist skin mul-
tidisciplinary teams questioned had arranged testing of tumour
blocks (from either primary or secondary melanoma tissue) for
BRAF mutations within the preceding 2 years (NICE 2015a). Al-
though genetic testing (or genotyping) may be carried out at the
same time at staging investigations, its purpose is to inform sys-
temic treatment decision rather than being an integral part of the
staging procedure itself.
Biomarkers, such as S100, are used in countries such as Germany
as a marker of prognosis (Gray 2014) or of early disease relapse
(Peric 2011) rather than for staging purposes per se (Egberts 2010;
Pirpiris 2010), whilst lactate dehydrogenase LDH is part of AJCC
staging for stage IV (Pirpiris 2010); however, these are beyond the
scope of our reviews.
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Rationale
Appropriate staging of melanoma is crucial to ensuring that pa-
tients are directed to the most appropriate and effective treatment.
A number of tests are available to assist in the staging of melanoma;
however, their comparative accuracy for detection of nodal, or dis-
tant metastases, or both, according to histological stage at presen-
tation is unclear.
The NICE guideline recommendations for staging (see Clinical
pathway) were based on available systematic reviews of both SLNB
and imaging tests (Hall 2013; Jimenez-Requena 2010; Krug 2008;
Rodriguez 2014; Valsecchi 2011; Xing 2011), with some supple-
mentary data from primary studies (NICE 2015d). The major-
ity of reviews are limited in terms of currency (de Rosa 2011;
Jimenez-Requena 2010; Krug 2008; Valsecchi 2011; Warycha
2009; Xing 2011), with literature searches in most cases extend-
ing only as recently as 2009 (Jimenez-Requena 2010; Krug 2008;
Valsecchi 2011; Xing 2011). Furthermore, the only one of these
to compare accuracy across imaging tests did not consider histo-
logical stage (Xing 2011). Two reviews provide a more recent eval-
uation of PET and PET-CT (search dates up to 2012 and 2011
respectively) (Rodriguez 2014; Schroer-Gunther 2012); however,
the Schroer-Gunther 2012 review also relied on previously pub-
lished reviews (Jimenez-Requena 2010; Krug 2008), with supple-
mentary searching for more recently published studies, and the
Rodriguez 2014 review included only stage III melanoma. The
Schroer-Gunther 2012 review relied on quality assessment that
was carried out for the original systematic reviews, and only a small
number of studies were eventually included; the authors them-
selves recommend that future reviews should include a broader
range of study designs (Schroer-Gunther 2012).
The comparative accuracy of imaging tests according to stage of
disease, therefore remains to be determined. Furthermore, any
evidence for or against the routine use of brain scanning in stage III
melanoma, either with CT or MRI, is yet to be determined. PET-
CT is increasingly used but any additional role it has compared
with CT or MRI needs to be examined according to particular
patient groups.
Our approach will allow the accuracy of each individual test to be
established (where possible according to stage of disease) and com-
parative accuracy to be summarised in a Cochrane DTA overview.
This approach will allow a complex topic to be approached in
stages, making the data more accessible and allowing the reader to
focus on individual tests. The overview review will compare those
tests for which there is sufficient evidence, exploiting within-study
comparisons of tests and allowing the analysis and comparison of
different diagnostic strategies.
This generic protocol provides the methodology that we will use
for a suite of reviews of tests to assist in the staging of melanoma.
We will tailor accordingly the background sections for each indi-
vidual test review and the overview review.
O B J E C T I V E S
To determine the diagnostic accuracy of SLNB for the detection of
nodal metastases (in the investigated nodal basin) for the staging
of cutaneous invasive melanoma.
To determine the diagnostic accuracy of imaging tests for the de-
tection of any metastasis in the primary staging of cutaneous in-
vasive melanoma (i.e. staging at presentation).
To determine the diagnostic accuracy of imaging tests for the de-
tection of any metastasis in the staging of recurrence in cutaneous
invasive melanoma (i.e. re-staging prompted by findings on rou-
tine follow-up).
Secondary objectives
To determine the diagnostic accuracy of imaging tests for the de-
tection of nodal metastases in the staging of cutaneous invasive
melanoma.
To determine the diagnostic accuracy of imaging tests for the de-
tection of distant metastases in the staging of cutaneous invasive
melanoma.
These will be estimated separately for those undergoing primary
staging and those who have experienced a disease recurrence.
Investigation of sources of heterogeneity
We will consider a range of potential sources of heterogeneity
for investigation in each individual test review. These may vary
between reviews but may include the following.
i. Population characteristics
• AJCC stage of disease
• Sentinel lymph node status (for imaging studies only)
• Clinical nodal status (for imaging studies only)
• Primary tumour site (head and neck, trunk, limb, and
other)
ii. Index test characteristics
• Differences in test positivity thresholds (e.g. for SLNB, the
tracer threshold for a ’hot’ versus ’cold’ node)
• Other relevant test characteristics as appropriate to the test
under consideration
iii. Reference standard characteristics
• Reference standard used (histology, clinical or imaging-
based follow-up; concurrent imaging-based reference standard)
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iv. Study quality
• Consecutive or random sample of participants recruited
• Index test interpreted, blinded to the reference standard
result
• Index test interpreted, blinded to the result of any other
index test
• Presence of partial or differential verification bias (whereby
only a sample of those subject to the index test are verified by the
reference test or by the same reference test, with selection
dependent on the index test result)
• Use of an adequate reference standard
• Overall risk of bias
We will examine the quality and quantity of research evidence
available on the effectiveness of each index test for the primary
target condition and make recommendations regarding where fur-
ther research might be required.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include test accuracy studies that allow comparison of
results of the index test with that of a reference standard, including:
• prospective and retrospective studies;
• studies where all participants receive a single index test and
a reference standard;
• studies where all participants receive more than one index
test(s) (concurrently) and a reference standard;
• studies where participants are allocated (by any method) to
receive different index tests or combinations of index tests and all
receive a reference standard (between-person comparative
studies);
• studies that recruit a series of participants unselected by
true disease status; and
• diagnostic case-control studies that separately recruit
diseased and nondiseased groups (Rutjes 2005).
We will exclude follow-up or surveillance studies using repeated
imaging tests to detect disease recurrence, as defining the most
appropriate follow-up schedule for melanoma patients is not the
primary objective of these reviews. We will exclude studies if it is
not possible to derive the number of true positives, false positives,
false negatives and true negatives from data provided in the paper,
or small studies with less than five disease-positive or less than five
disease-negative participants. Although the size threshold of five is
arbitrary, such small studies are likely to give unreliable estimates
of sensitivity or specificity, and may be biased in a similar way to
small randomised controlled trials (RCTs) of treatment effects.
We will include studies reporting either lesion-based or patient-
based analyses; however, we will only include those reporting data
on a per patient basis in the primary analysis. This is particularly
pertinent for the reviews of imaging tests where multiple metastatic
sites may be detected in an individual patient.
Participants
We will include studies in adults with cutaneous melanoma at any
primary site who are undergoing staging, either following primary
presentation of disease or following recurrence of disease. We will
include studies that include mixed populations of patients or where
the clinical pathway cannot be determined and examine any effect
on test accuracy in subgroup analysis. We will exclude studies
in which test results for participants with melanoma cannot be
differentiated from those of participants with other diagnoses.
For studies of sentinel lymph node biopsy (SLNB), outcomes must
be presented for both sentinel lymph node positive and sentinel
lymph node negative participants. For studies of imaging tests,
we will include studies focusing on either sentinel lymph node
positive or sentinel lymph node negative participants.
Index tests
We will undertake individual reviews for SLNB and for the fol-
lowing imaging tests, either alone or in combination.
• Ultrasound (with or without subsequent fine needle
aspiration cytology (FNAC) or core biopsy)
• Computed tomography (CT) (non-contrast or contrast-
enhanced)
• Positron emission tomography (PET) or PET-CT (¹ FDG
only)
• Magnetic resonance imaging (MRI) (non-contrast or
contrast-enhanced)
SLNB studies may assess the effectiveness of methods of detection
of sentinel lymph nodes, for example using different tracers or
dyes or alternative imaging approaches. These will often compare
approaches in terms of number of diseased nodes identified and we
will exclude these unless an eligible reference standard, as described
below, has been used.
We will produce a comparative overview review to compare the
accuracy of tests, either alone or in combination.
Target conditions
The target condition for the SLNB review will necessarily be de-
fined differently according to the result of the index test as:
• for sentinel lymph node positive participants, the presence
of micrometastasis in the nodal basin investigated by the SLNB
procedure; or
10Tests to assist in the staging of cutaneous melanoma: a generic protocol (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• for sentinel lymph node negative participants, the
emergence of clinically detectable nodal disease or
macrometastases in the nodal basin investigated by the SLNB
procedure in the absence of evidence of distant metastases (i.e. a
false negative SLNB result will be considered to have occurred if
disease is proven to emerge only in the regional lymph nodes
with no spread to distant sites).
In the event of inadequate data, we will drop the requirement to
demonstrate the absence of distant metastases in sentinel lymph
node negative participants with regional nodal recurrence, and we
will consider the emergence of any nodal disease in the nodal basin
investigated by the SLNB procedure a sufficient definition of a
false negative result.
The target conditions for the imaging test reviews are the detection
of:
• any metastases,
• any nodal metastases, or
• any distant metastases.
The use of the same tests for the staging of cutaneous squamous
cell carcinoma (cSCC) is the subject of a separate protocol (Dinnes
2017).
Reference standards
Acceptable reference standards include:
• histology of lymph node or distant specimens, with samples
obtained by core biopsy, SLNB or lymph node dissection, for
index test positive participants;
• cytology of lymph node specimens, with samples obtained
by core biopsy, or fine needle aspiration, for index test positive
participants;
• clinical or radiological follow-up to identify nodal or
distant recurrence of at least six months, for index test negative
participants; or
• any combination of the above.
Studies using cross-sectional imaging-based reference standards,
i.e. a direct comparison of the index test compared to an alternative
reference standard imaging test, will not be eligible.
Search methods for identification of studies
The Information Specialist (Susan Bayliss) has carried out a com-
prehensive search for published and unpublished studies. As pre-
viously mentioned, a series of Cochrane Diagnostic Test Accuracy
(DTA) reviews on the diagnosis and staging of melanoma and ker-
atinocyte skin cancers is being carried out as part of a National
Institute for Health Research (NIHR) Programme Grant.
Electronic searches
We have conducted a single large literature search for the pro-
gramme grant, covering all conditions and tests. This allowed for
the screening of search results for potentially relevant papers for
all reviews at the same time. We formulated a MEDLINE scoping
search combining disease-related terms with terms related to the
test names, using both text words and subject headings. As most
records were related to the searches for tests for the staging of dis-
ease, we applied a filter using terms related to cancer staging and
to accuracy indices to the staging test search, to try to eliminate
irrelevant studies, e.g. those using imaging tests to assess treatment
effectiveness.
We screened a sample of 300 records that would be missed by ap-
plying this filter and adjusted the filter to make sure that we would
not miss any potentially relevant studies. The final search filter
(Appendix 2) reduces the overall numbers retrieved from MED-
LINE by around 6000. We cross-checked the final search result
against the list of studies included in five systematic reviews; our
search identified all but one of the studies, and this study is not in-
dexed on MEDLINE. The Information Specialist, Susan Bayliss,
has devised the search strategy, with input from the Information
Specialist from Cochrane Skin, Elizabeth Doney. We used no ad-
ditional limits.
We undertook further scoping searches to identify any relevant
systematic reviews or health technology assessments. In addi-
tion to general bibliographic databases, we also accessed specialist
databases with a focus on reviews of diagnostic test accuracy, such
as ARIF.
We have now searched the following bibliographic databases, re-
trieving a total of 33,994 unique records:
Published studies
The Cochrane Central Register of Controlled Trials (CENTRAL)
in the Cochrane Library; the Cochrane Database of Systematic
Reviews (CDSR) in the Cochrane Library; CRD Database of
Abstracts of Reviews of Effects (DARE); CRD HTA (Health
Technology Assessment) database; MEDLINE via OVID (from
1946); MEDLINE In-Process & Other Non-Indexed Citations
via OVID; Embase via OVID (from 1980); and CINAHL (Cu-
mulative Index to Nursing and Allied Health Literature) via EB-
SCO from 1960 to the present).
Unpublished studies
Conference Proceedings Citation Index (CPCI) via Web of Sci-
ence™ (from 1990); Zetoc (from 1993); and SCI Science Cita-
tion Index Expanded via Web of Science™ (from 1900), using
the “Proceedings and Meetings Abstracts” Limit function.
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Trials registers
The US National Institutes of Health Ongoing Trials Reg-
ister ClinicalTrials.gov (www.clinicaltrials.gov); NIHR Clinical
Research Network Portfolio Database (www.nihr.ac.uk/research-
and-impact/nihr-clinical-research-network-portfolio/); and the
World Health Organization International Clinical Trials Registry
Platform (apps.who.int/trialsearch).
We aimed to identify all relevant studies, regardless of language
or publication status (published, unpublished, in press, or in
progress). We applied no date limits. Update searches will be time-
and resource-dependent.
Searching other resources
Due to time restrictions and the volume of evidence retrieved from
the electronic searches, we will not conduct any handsearching of
conference proceedings. By searching CENTRAL, we will retrieve
relevant records identified by regular handsearching by Cochrane
Skin. The handsearched conferences and journals are listed here:
www.skin.cochrane.org/resources-handsearchers.
We will include information about potentially relevant ongoing
studies in the ’Characteristics of ongoing studies’ tables. We will
screen any relevant systematic reviews identified by the searches for
their included primary studies, and we will include any that our
searches have missed in the review. We will check the reference lists
of all included papers, and subject experts within the author team
will review the final list of included studies. We may use citation-
searching for key references when we consider it appropriate.
Data collection and analysis
Selection of studies
Due to the volume of records retrieved, at least one review au-
thor (JDi or NC) has undertaken screening of the titles and ab-
stracts, with any queries on the part of either reviewer discussed
and resolved by consensus. A pilot exercise independently screen-
ing 539 references from MEDLINE showed a good level of agree-
ment (89% with a kappa of 0.77). To date, 822 records have been
selected for full text review for the staging reviews. At least two
review authors, including methodologists (JDi or NC) and clin-
ical reviewers, using a study eligibility screening proforma based
on prespecified inclusion criteria, will independently undertake
subsequent assessment of potentially relevant full text articles for
the staging reviews (Appendix 3). Where differences in opinion
exist, a third party drawing on the clinical and methodological
expertise in the team, as appropriate to the content of the query
(JDe, CD, HW, and RM), will help with resolution. We will com-
pile a list of otherwise eligible studies for which insufficient data
were presented to allow for the construction of a 2x2 contingency
table, and we will contact study authors, asking them to provide
the relevant data. We will describe the study selection process in
an adapted PRISMA flowchart (Liberati 2009). At the full text
inclusion stage, we will tag studies according to their target con-
dition (melanoma or cSCC) and index test.
Data extraction and management
We will carry out data extraction using a predesigned and piloted
data extraction form using Excel to ensure that we collect relevant
data. At least two review authors will independently extract data
concerning details of the study design, participants, index test(s)
or test combinations and criteria for index test positivity, reference
standards, and data required to populate a 2x2 diagnostic con-
tingency table for each index test. We will record where data are
available at several index test thresholds. A third party drawing on
clinical and methodological expertise in the team as appropriate
to the content of the query will resolve discrepancies.
We will attempt to contact authors of included studies where in-
formation that is considered key to one or more of the assessments
of the quality of an included study, investigation of heterogeneity,
or completion of a 2x2 diagnostic contingency table is missing.
We will follow up studies published only as conference abstracts
to identify whether a subsequent full paper has been published.
Where possible, we will contact the authors of conference abstracts
published from 2015 to 2016 and ask whether full data are avail-
able. If we can identify no full paper, we will mark conference
abstracts as ’pending’ and revisit them. Experience of contacting
authors for information about missing data in DTA reviews is lim-
ited. Therefore, where we seek missing data, we will document the
outcome of contact with the authors.
Dealing with multiple publications and companion papers
In the event of multiple reports of a primary study, we will exam-
ine all available data to determine the potential for overlapping
populations and to identify a primary data source. Where we sus-
pect overlapping study populations and are unable to identify a
primary data source, we will contact study authors for clarification
in the first instance. If contact with authors is unsuccessful, we will
use the most complete and up-to-date data source available, thus
avoiding the risk of double-counting. We will examine the impact
of inconsistencies in reporting of 2x2 data that remain unresolved
in a sensitivity analysis.
Assessment of methodological quality
We will assess applicability and risk of bias of included studies
using the QUADAS-2 checklist (Whiting 2011), which has been
tailored to the review topic (see Appendix 4).
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Patient selection domain (1)
Selective recruitment of study participants can be a key influence
on test accuracy. In general terms, all participants eligible to un-
dergo a test should be included in a study, allowing for the in-
tended use of that test within the context of the study.
Inappropriate participant exclusions affecting the internal validity
of a study of staging might include exclusion of people with pri-
mary tumours at sites such as head and neck or exclusion of those
with unsuccessfully mapped sentinel lymph nodes.
For sentinel lymph node biopsy (SLNB) studies, the applicability
of a study’s results will be affected by the patient spectrum accord-
ing to the clinical stage of disease (AJCC stage) and site of the
primary tumour.
Imaging tests may be undertaken following diagnosis of the pri-
mary melanoma lesion or following disease recurrence, such that
studies may include mixed populations of participants. Given
the potential for variation in test accuracy according to patient
spectrum and disease prevalence (Brenner 1997; Leeflang 2013;
Mulherin 2002), the applicability of results will be affected by
the proportion of participants undergoing primary staging versus
staging for disease recurrence, as well as by the clinical stage of dis-
ease (AJCC stage or clinical nodal status) and site of the primary
tumour.
Index test domain (2)
Given the subjectivity of test interpretation, particularly for imag-
ing tests, the interpretation of the index test blinded to the re-
sult of the reference standard is a key means of reducing bias. For
prospective studies, the index tests will by nature be interpreted
before the result of the reference standard is known; however, ret-
rospective studies will be susceptible to information bias either if
the person abstracting data from medical records is aware of indi-
vidual patients’ final diagnoses, or if any reinterpretation of images
is undertaken for the purposes of the study.
For imaging tests, studies reporting the accuracy of multiple diag-
nostic thresholds (different tumour characteristics or parameters)
for the same index test will also be subject to information bias un-
less each characteristic was interpreted by a different reader. This
would be an impractical and unlikely approach for most studies,
but a quality item has been included in order to highlight any
studies where this occurs in order to allow discussion.
In terms of applicability, despite the often subjective nature of test
interpretation, it is important that study authors outline the par-
ticular characteristics that were considered to be indicative of the
presence of disease so that appropriate comparisons can be made
between test evaluations and the test can be replicated in practice.
For SLNB, a description of the tracer threshold for a ’hot’ versus
’cold’ node, as well as a description of the histology interpretation
(such as the Royal College of Pathologists) requirements will be
required.
The experience of the observer will also impact on the applicabil-
ity of study results. Detailed information on the experience and
training of care providers is often lacking, such that a detailed
analysis of the impact of examiner experience may not be possible.
However to be considered ’low concern’:
• surgical members of the specialist skin multidisciplinary
team should meet guideline recommendations, i.e. carrying out
at least 15 inguinal or axillary lymph node dissections per year
(NHS England 2014);
• imaging tests should be interpreted by consultant
radiologists.
Reference standard domain (3)
In an ideal study, consecutively recruited participants should all
undergo the same reference standard. In reality, both partial and
differential verification bias are likely.
Partial verification bias will occur where histology (e.g. complete
lymph node dissection) is the only reference standard used, and
only those participants with a certain degree of suspicion of ma-
lignancy based on the result of the index test undergo verification,
the others either being excluded from the study or being defined
as being disease-negative without further assessment or follow-up.
Cytology cannot be used as the only reference standard due to the
potential for relatively high false negative rates; however a positive
cytology result is considered equally as valid as a histology result
in the majority of the cases (with the exception of poorly differ-
entiated tumours).
Differential verification bias will be present where other reference
standards are used in addition to histological or cytological veri-
fication. Differential verification is inevitable in these reviews be-
cause of the invasive nature of obtaining tissue samples for his-
tological confirmation of presence/absence of malignancy. This is
particularly true where complete lymph node dissection is the ref-
erence standard for detection of nodal metastases, as this will not
be undertaken in those who have a negative SLNB. With imaging
tests, histological confirmation would be impossible following a
negative imaging result, however those with borderline or indeter-
minate results are also unlikely to have subsequent histology. Any
indeterminate results will be reviewed by the multidisciplinary
team and a decision made whether to repeat the imaging in three
months for example, or to image with a different modality to clar-
ify. With borderline imaging the finding is usually too small to call
a metastasis, making biopsy very unlikely for practical reasons.
Absence of disease in index test negative participants and in those
negative on cytology will require confirmation by clinical or ra-
diological follow-up. Ideally, a follow-up based reference standard
should be long enough to allow all present but ’hidden’ cases of
disease to become detectable (Naaktgeboren 2013), however dif-
ferentiating disease that was originally present but missed from
newly emergent disease is problematic, particularly given the slow
growing nature of disease. No upper time limit has therefore been
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applied to define an ’adequate’ follow-up reference standard.
For the SLNB review, we will require studies to report the emer-
gence of clinically detectable or macroscopic nodal disease in an
investigated nodal basin for sentinel lymph node negative partic-
ipants in order to be included; for the reference standard to be
judged adequate however, we will require studies to report disease
occurrence in a mapped nodal basin. For the imaging reviews, we
will define an adequate reference standard for imaging test nega-
tive participants as clinical or radiological follow-up to detect any
metastatic disease. We will consider studies that use a concurrently
applied imaging test to determine final diagnosis of index test neg-
ative participants at high risk of bias.
A further challenge is the potential for incorporation bias, i.e.
where the result of the index test is used to help determine the
reference standard diagnosis. For both SLNB and imaging tests,
only those with positive test results will undergo any procedure
to allow histological confirmation (whether core biopsy, SLNB or
complete lymph node dissection). In each case, the histopatholo-
gist will most likely be aware that the index test was positive and
this knowledge will inform the pathology procedure.
There is also considerable potential for the clinicians or radiologists
concerned with the clinical follow-up, radiological follow-up, or
both, of study participants to identify any subsequent emergence
of nodal or distant disease to be aware of the original index test
result and to use that to inform diagnostic decisions at the time of
follow-up.
Reference standard blinding is therefore extremely unlikely and
its enforcement would significantly limit the generalisability of
the study results. We will therefore assess the presence of blinded
reference test interpretation (as it is a standard QUADAS-2 item)
but will not include it in our overall assessment of bias.
Flow and timing domain (4)
A period of one month has been defined as an appropriate interval
(low risk of bias) between application of the index test and a his-
tological reference standard (complete lymph node dissection or
biopsy of possible distant metastases). Where the reference stan-
dard is follow-up based, we have not applied any restrictions on
follow-up timing.
Comparative domain
In the event that we identify comparative primary test accuracy
studies and include them in the overview, we will add a compar-
ative domain to the QUADAS-2 checklist (Appendix 4). Ques-
tions reflect the possibility of selection bias (into the study and
allocation to index test or testing strategies) and assessment of
blinding of interpretation of each individual index test for within-
person comparisons. In addition, for within-person test compar-
isons, we have specified a maximum of one month between ap-
plication of individual index tests, as intervals greater than these
may be accompanied by changes in tumour characteristics. This
is an arbitrary threshold, and in the event that a large proportion
of included studies exceed this time period, we will undertake a
sensitivity analysis to investigate the impact of this quality item
on estimates of accuracy.
We will initially pilot the amended checklist tool on a small num-
ber of included full text articles. Independently, two review au-
thors will rate each study on the four quality domains (patient
selection, index test(s), reference standard, flow and timing). They
will resolve any disagreements by consensus or by referral to a third
review author.
We will narratively summarise the results of quality assessment for
all included studies at domain level, highlighting those domains
that pose the greatest potential for risk of bias and concern about
applicability for the body of evidence. We will supplement the nar-
rative summary with summary graphics and tables as appropriate
to assist with the presentation of the results of quality assessment
across included studies for important participant subgroups and
by index test.
Statistical analysis and data synthesis
For the SLNB reviews, our primary analysis will focus on the de-
tection of metastases in the investigated nodal basin. For the imag-
ing test reviews, we will conduct separate analyses firstly according
to whether study participants are recruited on primary presenta-
tion of melanoma or with a disease recurrence, and secondly ac-
cording to our primary and secondary objectives, i.e. detection of
any metastasis (which must include both nodal and distant recur-
rence) and detection of nodal metastasis alone or detection of any
distant metastasis, as defined under ’Target condition’). SLNB is
not employed for staging of recurrence in skin cancer.
Studies may report test accuracy per-lesion or per-patient. Our
unit of analysis for the primary analyses will be the patient as study
participants may have multiple metastatic sites at any one time,
such that a per lesion analysis may over-estimate test accuracy. We
will include data from studies that reported per-lesion level data in
secondary analyses, such that per lesion and per patient data from
different studies would be combined together, using per patient
data in preference where both are reported within a study. The
estimation of the accuracy metrics to be used in our reviews are
detailed in Appendix 5.
For the SLNB review, both index test and reference standard pos-
itivity are defined histologically. In the absence of an additional
suitable reference standard for SLNB test positivity, it will not be
possible to estimate false positive cases and specificity will always
be 100%. We will therefore perform meta-analysis of only sen-
sitivities by using a univariate random effects logistic regression
model. We will also estimate the pooled negative predictive value
in a secondary analysis (the positive predictive value not being
possible to calculate due to false positives not being estimable).
The definitions for each cell of the 2x2 contingency tables for the
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SLNB review are as follows.
• TP = sentinel lymph node positive (i.e. all patients with a
positive sentinel lymph node regardless of any subsequent
recurrence).
• FP = not possible to estimate.
• FN = sentinel lymph node negative patients who experience
clinical emergence of disease in the same nodal basin, in the
absence of disseminated disease.
• TN = sentinel lymph node negative patients who do not
experience clinical emergence of disease in the same nodal basin.
For the imaging test reviews, we will estimate sensitivity and speci-
ficity in the usual way. We will initially explore the data by plot-
ting estimates of sensitivity and specificity on coupled forest plots
and in receiver operating characteristic (ROC) space for each in-
dex test under consideration. We will use hierarchical models to
perform meta-analyses (Macaskill 2010). Where commonly used
thresholds are reported, we will produce summary operating points
(summary sensitivities and specificities) with 95% confidence and
prediction regions using the method in Reitsma 2005. Where dif-
ferent thresholds are used, we will fit a summary curve using the hi-
erarchical summary ROC model (Rutter 2001). When few studies
are available for meta-analysis, we will simplify hierarchical mod-
els as appropriate, depending on whether the focus of inference is
a summary point or summary curve (Takwoingi 2015). It is antic-
ipated that results from multiple thresholds within a single study
may be reported in many instances. Where multiple thresholds
are to be selected for the review, data from the same participants
may be used more than once in each analysis. For the analysis of
summary curves, however, we will select standard or most com-
monly used thresholds from each study; failing that, we will select
one threshold at random.
For the overview, we will perform both direct and indirect test
comparisons, the latter being required because it is anticipated that
comparative studies may be scarce (Takwoingi 2013). To formally
compare index tests, we will add a covariate for test type to a
hierarchical model. We will use likelihood ratio tests to assess the
statistical significance of differences in test accuracy (sensitivity
and specificity) for analyses of summary points and shape and
accuracy for analyses of summary curves, by comparing models
without the covariate terms with models containing the covariate
terms.
We will conduct analyses using Review Manager 5 (Review
Manager 2014), the NLMIXED procedure in the statistical soft-
ware SAS version 9.4 (SAS 2016) and the meqrlogit command in
the statistical software STATA 15 (STATA 2017).
Investigations of heterogeneity
We will initially examine heterogeneity between studies by visu-
ally inspecting the forest plots of sensitivity and specificity and
summary ROC plots. Where a sufficient number of studies has
assessed the same index test and the characteristics of interest (see
Secondary objectives) were adequately reported to enable analyses,
we will perform meta-regression by adding the potential source of
heterogeneity as a covariate to a hierarchical model. We will apply
a minimum requirement of at least five studies in each subgroup;
we will only report heterogeneity analyses with less than five stud-
ies per group when we can be convinced that models have achieved
adequate convergence and that the distribution of studies across
groups is adequate to provide valid estimates. Where factors to
be investigated (e.g. AJCC stage of disease) could vary between
participants within a study, we will rely on the inclusion criteria
set out by study authors (such as restriction to stage II or to stage
III or IV melanoma), or use the results of any subgroup analyses
within a study to examine the effect of that covariate. We will as-
sess each of the factors listed under the secondary objectives where
possible.
Sensitivity analyses
If a sufficient number of studies assess the same index test, we will
perform sensitivity analyses restricting analyses according to:
• those with direct test comparisons (where the period of
application between the index tests was within one month);
• where concerns around applicability for participant
selection are low;
• where there was low risk of bias for the index test; and
• where there was low risk of bias for the reference standard.
As for the Investigations of heterogeneity above, we will require
a minimum of at least five studies before we conduct sensitivity
analyses.
Assessment of reporting bias
Because of uncertainty about the determinants of publication bias
for diagnostic accuracy studies and the inadequacy of tests for de-
tecting funnel plot asymmetry (Deeks 2005), we will not perform
tests to detect publication bias.
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A D D I T I O N A L T A B L E S
Table 1. Glossary of terms
Term Definition
Adjuvant therapy or treatment A treatment given after the main treatment for cancer to reduce the risk of recurrence
Adverse event Detrimental change in health occurring in a person receiving the treatment whether or
not it has been caused by the treatment
Axillary In the armpit.
Biopsy Removal of a sample of tissue from the body to assist in diagnosis or inform the choice
of treatment of a disease
BRAF V600 mutation BRAF is a human gene that makes a protein called B-Raf which is involved in the control
of cell growth. BRAF mutations (damaged DNA) occur in around 40% of melanomas,
which can then be treated with particular drugs
BRAF inhibitors Therapeutic agents which inhibit the serine-threonine protein kinase BRAF mutated
metastatic melanoma
Breslow thickness A scale for measuring the thickness of melanomas by the pathologist using a microscope,
measured in mm from the top layer of skin to the bottom of the tumour
Cervical (lymph nodes) Lymph nodes found in the neck area of the body.
Computed tomography (CT) Imaging technique in which the person lies on a table within an x-ray gantry. The images
are acquired using a spiral (helical) path and banks of detectors, allowing presentation
of the internal organs and blood vessels in different projections including 3-D views
Coronal Frontal plane dividing the body into front and back.
False negative An individual who is truly positive for a disease, but whom a diagnostic test classifies
them as disease-free
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Table 1. Glossary of terms (Continued)
False positive An individual who is truly disease-free, but whom a diagnostic test classifies them as
having the disease
Histopathology The study of tissue, usually obtained by biopsy or excision, for example under a micro-
scope
Incidence The number of new cases of a disease in a given time period.
Inguinal Lymph nodes in or just above or just below the groin.
Isolated limb perfusion A medical procedure that directly delivers a drug through the bloodstream in a limb to
the site affected by melanoma
Local recurrence Regrowth of a tumour in the area from which it was originally removed
Locoregional recurrence Regrowth of a tumour in the area from which it was originally removed or in the regional
lymph nodes (usually nearest to the original tumour site)
Lymph node Lymph nodes filter the lymphatic fluid (clear fluid containing white blood cells) that
travels around the body to help fight disease; they are located throughout the body often
in clusters (nodal basins)
Lymph node dissection Surgical removal or one or more lymph nodes in the absence of proven involvement with
melanoma
Lymphadenectomy Lymphadenectomy or lymph node dissection is a surgical operation to remove one or
more groups of lymph nodes
Lymphoscintigraphy An imaging technique used to identify the lymph drainage basin, determine the number
of sentinel nodes, differentiate sentinel nodes from subsequent nodes, locate the sentinel
node in an unexpected location, and mark the sentinel node over the skin for biopsy. It
requires the injection of a radioisotope into the skin around the biopsy scar and a scan
some hours later to determine to which lymph nodes the tracer has travelled
Lymphovascular invasion Tumour cells which have spread to involve the blood vessels and lymphatic vessels within
the skin
Magnetic resonance imaging (MRI) A type of scan which uses a magnetic field and radio waves to produce images of sections
of the body
Mediastinal and hilar adenopathy Enlargement of the pulmonary lymph nodes.
MEK inhibitors Drugs that inhibit the mitogen-activated protein kinase enzymes which are often upreg-
ulated in melanoma
Meta-analysis A form of statistical analysis used to synthesise results from a collection of individual
studies
23Tests to assist in the staging of cutaneous melanoma: a generic protocol (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Glossary of terms (Continued)
Metastases/metastatic disease Spread of cancer away from the primary site to somewhere else through the bloodstream
or the lymphatic system
Micrometastases Micrometastases are metastases so small that they can only be seen under a microscope
Mitotic rate Microscopic evaluation of number of cells actively dividing in a tumour
Morbidity Detrimental effects on health.
Mortality Either (1) the condition of being subject to death; or (2) the death rate, which reflects
the number of deaths per unit of population in relation to any specific region, age group,
disease, treatment or other classification, usually expressed as deaths per 100, 1000, 10,
000 or 100,000 people
Multidisciplinary team A team with members from different healthcare professions and specialties (e.g. urology,
oncology, pathology, radiology, and nursing). Cancer care in the National Health Service
(NHS) uses this system to ensure that all relevant health professionals are engaged to
discuss the best possible care for that patient
Nodal basin Cluster of lymph nodes which filter lymphatic fluid as it travels around the body; clusters
are located under the arm (axilla), in the groin, neck, chest and abdomen
Oncology The study of cancers. This term also refers to the medical specialty of cancer care, with
particular reference to the use of radiotherapy or drugs to treat cancer. The medical
specialty is often split into clinical oncology (doctors who use radiotherapy and drug
treatment) and medical oncology (doctors who use drug treatment)
Palpation Feeling with the fingers or hands as part of a clinical examination of the body
Positron emission tomography (PET) A nuclear medicine imaging technique whereby a radioactive glucose (usually 18FDG) is
administered intravenously before a scan is conducted to create an image using colours
to show where the FDG (or other radioactive tracer) has been taken up in the body
Prevalence The proportion of a population found to have a condition.
Prognostic factors/indicators Specific characteristics of a cancer or the person who has it which might affect the patient’s
prognosis
Radiotherapy The use of radiation, usually high energy x-rays to control the growth of cancer cells
RAS-RAF-MEK-ERK signalling pathway A chain of proteins which allow signals from a receptor on the surface of a cell to be
sent to the DNA in the cell nucleus; a mutation in one of the proteins in the pathway is
associated with the development of many cancers
Recurrence Recurrence is when new cancer cells are detected following treatment. This can occur
either at the site of the original tumour or at other sites in the body
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Table 1. Glossary of terms (Continued)
Relapse Where cancer starts to grow again after treatment.
Sagittal Median plane dividing the body into left and right.
Sensitivity In this context the term is used to mean the proportion of individuals with a disease who
have that disease correctly identified by the study test
Sentinel lymph node biopsy (SLNB) A radioactive tracer and blue dye are injected into the skin surrounding the primary lesion
and the ’sentinel’ lymph nodes to which the tracer drains are located by imaging (usually
lymphoscintigraphy) and then removed and examined for nodal metastatic spread that
cannot be detected clinically or on imaging
Signal transduction Occurs when extracellular signalling molecules activate a specific receptor which then
triggers cellular pathways
Staging Clinical description of the size and spread of a patient’s tumour, fitting into internationally
agreed categories
Stereotactic radiotherapy A technique for delivering high dose radiotherapy very accurately to small areas inside
the body which reduces the damage done by the radiotherapy to adjacent healthy tissues
Subclinical (disease) Disease that is usually asymptomatic and not easily observable, e.g. by clinical or physical
examination
Systemic treatment Treatment, usually given by mouth or by injection, that reaches and affects cancer cells
throughout the body rather than targeting one specific area
Ultrasound A type of scan in which high-frequency sound waves are used to outline a part of the
body
Some of the definitions above have been obtained from the NICE Guideline for the management of melanoma (NICE 2015a).
Table 2. American Joint Committee on Cancer (AJCC) staging for cutaneous melanoma
a. TNM staging categories for cutaneous melanoma
Classification
T Thickness (mm) Ulceration status/mitoses
Tis NA NA
T1 <= 1.00 a: Without ulceration and mitosis 1/mm2
b: With ulceration or mitoses 1/mm2
T2 1.01 to 2.00 a: Without ulceration
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Table 2. American Joint Committee on Cancer (AJCC) staging for cutaneous melanoma (Continued)
b: With ulceration
T3 2.01 to 4.00 a: Without ulceration
b: With ulceration






N1 1 a: Micrometastasis*
b: Macrometastasis†
N2 2 to 3 a: Micrometastasis*
b: Macrometastasis†
c: In transit metastases/satellites without metastatic nodes
N3 4 metastatic nodes, or
mat-
ted nodes, or in tran-
sit metastases/satellites
with metastatic nodes
M Site Serum LDH
M0 No distant metastases NA
M1a Distant skin, subcuta-
neous, or nodal metas-
tases
Normal
M1b Lung metastases Normal
M1c All other visceral
metastases
Normal
Any distant metastasis Elevated
b. Anatomical stage groupings
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0 Tis N0 M0 0 Tis N0 M0
IA T1a N0 M0 IA T1a N0 M0
IB T1b N0 M0 IB T1b N0 M0
T2a N0 M0 T2a N0 M0
IIA T2b N0 M0 IIA T2b N0 M0
T3a N0 M0 T3a N0 M0
IIB T3b N0 M0 IIB T3b N0 M0
T4a N0 M0 T4a N0 M0
IIC T4b N0 M0 IIC T4b N0 M0
III Any
T
N > N0 M0 IIIA T1- T4a N1a M0
T1- T4a N2a M0
IIIB T1- T4b N1a M0
T1- T4b N2a M0
T1- T4a N1b M0
T1- T4a N2b M0
T1- T4a N2c M0
IIIC T1- T4b N1b M0
T1- T4b N2b M0
T1- T4b N2c M0
Any T N3 M0
IV Any
T
Any N M1 IV Any T Any N M1
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LDH - lactate dehydrogenase; M - metastasis; N - nodes; NA - not applicable; T - tumour; Tis - melanoma in situ.
*Micrometastases are diagnosed after sentinel lymph node biopsy.
†Macrometastases are defined as clinically detectable nodal metastases confirmed pathologically.
‡Clinical staging is based on histology of the primary lesion and clinical (or radiological) examination.
δPathologicalstagingisassignedbasedonhistologyof theprimarylesionandof theregionallymphnodes(eithersentinellymphnodebiops
A P P E N D I C E S
Appendix 1. Current content and structure of the Programme Grant
LIST OF REVIEWS Estimated number of studies
Diagnosis of melanoma
1 Visual inspection 50
2 Dermoscopy 88
3 Teledermatology 15
4 Mobile phone applications 2
5a Computer-aided diagnosis - dermoscopy-based techniques 37
5b Computer-aided diagnosis - spectroscopy-based techniques This review will be amalgamated into 5a
6 Reflectance confocal microscopy 19
7 High frequency ultrasound 5
8 Overview: Comparing the accuracy of tests for which sufficient
evidence is identified either alone or in combination
Number not estimable
Diagnosis of keratinocyte skin cancer (BCC and cSCC)
9 Visual inspection +/- Dermoscopy 22
10a Computer-aided diagnosis - dermoscopy-based techniques 3
10b Computer-aided diagnosis - spectroscopy-based techniques This review will be amalgamated into 10a
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(Continued)
11 Optical coherence tomography 5
12 Reflectance confocal microscopy 9
13 Exfoliative cytology 9
14 Overview: Comparing the accuracy of tests for which sufficient
evidence is identified either alone or in combination
Number not estimable
Staging of melanoma
15 Ultrasound 25 - 30
16 CT 5 - 10
17 PET or PET-CT 20 - 25
18 MRI 5
19 Sentinel lymph node biopsy +/- high frequency ultrasound 70
20 Overview: Comparing the accuracy of tests for which sufficient
evidence is identified either alone or in combination
Number not estimable
Staging of cSCC
21 Imaging tests review 10 - 15
22 Sentinel lymph node biopsy +/- high frequency ultrasound 15 - 20
Appendix 2. MEDLINE (OVID) search strategy
Database: Ovid MEDLINE(R) <1946 to August 2016 (as run on 28 August 2016) FINAL
Amended Search Strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 exp Neoplasms, basal cell/
5 basalioma$1.ti,ab.
6 ((basal cell or skin) adj2 (cancer$ or carcinoma$1 or mass or masses or tumour$ or tumor$ or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
7 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
8 (melanom$ or nonmelanoma$ or non-melanoma$ or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
9 nmsc.ti,ab.
10 rodent ulcer$.ti,ab.
11 (squamous cell adj2 (cancer$ or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
12 (BCC or CSCC or NMSC).ti,ab.
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19 exp epiluminescence microscopy/
20 Microscopy, Confocal/
21 (epiluminescence adj2 microscop$).ti,ab.
22 (confocal adj2 microscop$).ti,ab.
23 Tomography, Optical Coherence/
24 Dielectric Spectroscopy/
25 Cytodiagnosis/
26 (incident light adj2 microscop$).ti,ab.
27 (surface adj2 microscop$).ti,ab.
28 (visual adj (inspect$ or examin$)).ti,ab.



























56 (high adj3 ultraso$).ti,ab.
57 (canine adj2 detect$).ti,ab.
58 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
59 smartphone$.ti,ab.
60 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
61 Mole Detective.ti,ab.
62 Spot Check.ti,ab.
63 (mole$1 adj2 map$).ti,ab.
64 (total adj2 body).ti,ab.
65 exfoliative cytolog$.ti,ab.
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66 digital analys$.ti,ab.
67 (imag$ adj3 software).ti,ab.
68 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
69 (optical coherence adj (technolog$ or tomog$)).ti,ab.
70 OCT.ti,ab.
71 (computer adj2 diagnos$).ti,ab.
72 exp sentinel lymph node biopsy/)
73 (sentinel adj2 node).ti,ab.
74 nevisense.mp. or HFUS.ti,ab.
75 electrical impedance spectroscopy.ti,ab.
76 history taking.ti,ab
77 patient history.ti,ab.
78 (naked eye adj (exam$ or assess$)).ti,ab.
79 (skin adj exam$).ti,ab.
80 physical examination/
81 ugly duckling.mp. or UD.ti,ab.
82 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
83 ABCDE.mp. or VOC.ti,ab.
84 clinical accuracy.ti,ab.
85 Family Practice/ or Physicians, Family/ or clinical competence/




90 volatile organic compound$1.ti,ab.
91 dog$1.ti,ab.
92 gene expression analy$.ti,ab.




97 (CT or PET).ti,ab.
98 PET-CT.ti,ab.




103 CATSCAN.ti,ab. 104 exp Tomography, Emission-Computed/
105 exp Tomography, X-ray computed/
106 positron emission tomograph$.ti,ab.
107 exp magnetic resonance imaging/






114 magnetic resonance imag$.ti,ab.
115 or/97-114 (1337432)
116 (stage$ or staging or metasta$ or recurr$ or advanced or sensitivity or specificity or false negative$ or thickness$).ti,ab.
117 “Sensitivity and Specificity”/
118 exp cancer staging/
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119 or/116-118 (2164365)
120 115 and 119
121 96 or 120
122 15 and 121 (18542)
Appendix 3. Full-text exclusion criteria
The study: Response (enter X if any of the exclusion criteria are met)
• is not a primary study
• is a conference abstract only
• is a systematic review
• does not allow accuracy to be estimated separately for either
melanoma or cSCC participants
• (for SLNB) does not report outcomes for both SLN+ and
SLN- patients
• (for SLNB) does not report recurrence in the investigated
nodal basin
• (for imaging) does not report detection of nodal or distant
recurrence (or any recurrence)
• (for melanoma only) includes < 5 diseased or < 5
nondiseased participants
• (for cSCC) no sample size limit
• evaluates an ineligible index test (eligible tests are SLNB,
US, CT, PET or PET-CT, MRI)
• is a surveillance (follow-up) study using repeat or serial
imaging
• does not use an eligible reference standard
• does not assess test accuracy (i.e. 2 x 2 cannot be derived)
cSCC: cutaneous squamous cell carcinoma.
SLNB: sentinel lymph node biopsy.
US: ultrasound.
CT: computed tomography.
PET: positron emission tomography.
PET-CT: positron emission tomography-computed tomography.
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MRI: magnetic resonance imaging.
Appendix 4. QUADAS interpretation
Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
1) Was a consecutive or random sample of participants or images
enrolled?
Yes - if paper states consecutive or random
No - if paper describes other method of sampling
Unclear - if participant sampling not described
2) Was a case-control design avoided? Yes - if consecutive or random or case-control design clearly not
used
No - if study described as case-control or describes sampling spe-
cific numbers of participants with particular diagnoses
Unclear - if not described
3) Did the study avoid inappropriate exclusions, e.g. needs ex-
amples of inappropriate exclusions in this context - for both
melanoma and for cutaneous squamous cell carcinoma (cSCC)
staging?
Yes - if inappropriate exclusions were avoided
No - if lesions were excluded that might affect test accuracy, e.g.
indeterminate results or where disagreement between evaluators
was observed
Unclear - if not clearly reported
4) For between-person comparative (BPC) studies only (i.e. allo-
cating different tests to different study participants such as ran-
domised controlled trials (RCTs)):
• a) were the same participant selection criteria used for those
allocated to each test?
Yes - if same selection criteria were used for each index test
No - if different selection criteria were used for each index test
Unclear - if selection criteria per test were not described
N/A - if only one index test was evaluated or all participants re-
ceived all tests
• b) was the potential for biased allocation between tests
avoided through adequate generation of a randomised sequence?
Yes - if adequate randomisation procedures are described
No - if inadequate randomisation procedures are described
Unclear - if the method of allocation to groups is not described
(a description of ‘random’ or ‘randomised’ is insufficient)
N/A - if only one index test was evaluated or all participants re-
ceived all tests
• c) was the potential for biased allocation between tests
avoided through concealment of allocation prior to assignment?
Yes - if appropriate methods of allocation concealment are de-
scribed
No - if appropriate methods of allocation concealment are not
described
Unclear - if the method of allocation concealment is not described
(sufficient detail to allow a definite judgement is required)
N/A - if only one index test was evaluated
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Could the selection of participants have introduced bias?
v FOR NON-COMPARATIVE (NC) STUDIES
If answers to all of questions 1) and 2) and 3) was ‘Yes’: Risk is Low
If answers to any one of questions 1) or 2) or 3) was ‘No’: Risk is High
If answers to any one of questions 1) or 2) or 3) was ‘Unclear’: Risk Unclear
v FOR BETWEEN-PERSON COMPARATIVE STUDIES
If answers to all of questions 1) and 2) and 3) and 4) was ‘Yes’: Risk is Low
If answers to any one of questions 1) or 2) or 3) or 4) was ‘No’: Risk is High
If answers to any one of questions 1) or 2) or 3) or 4) was ‘Unclear’: Risk Unclear
PARTICIPANT SELECTION (1) - CONCERNS REGARDING APPLICABILITY
For sentinel lymph node biopsy and imaging tests:
1) Does the study report results for participants unselected by stage
of disease or site of primary lesion, i.e. the study does not focus
solely on those with a particular stage of disease such as AJCC I
or melanoma <=1 mm in thickness?
Yes - if an unrestricted group of participants have been included
No - if a selected group of study participants have been included,
e.g. those with clinical stage I disease or only those with thin
melanoma
Unclear - if insufficient details are provided to determine the
spectrum of included participants
2) Did the study report data on a per-patient rather than per-
lesion basis?
Yes - if a per-patient analysis was reported
No - if a per-lesion analysis only was reported
Unclear - if it is not possible to assess whether data are presented
on a per-patient or per-lesion basis
For imaging tests only:
3) Does the study focus primarily on participants undergoing pri-
mary staging or those undergoing staging for disease recurrence?
Yes - if at least 80% of study participants are undergoing primary
staging following diagnosis of a primary cutaneous melanoma or
staging of recurrence
No - if less than 80% of study participants are undergoing primary
staging following diagnosis of a cutaneous melanoma or staging
of recurrence
Unclear - if insufficient details are provided to determine the
proportion of patients undergoing primary staging versus those
undergoing staging of recurrence
Is there concern that the included participants do not match the review question?
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If the answer to question 1) or 2) (and 3)) was ‘Yes’: Concern is Low
If the answer to question 1) or 2) (and 3)) was ‘No’: Concern is High
If the answer to question 1) or 2) (and 3)) was ‘Unclear’: Concern is Unclear
INDEX TEST (2) - RISK OF BIAS (to be completed per test evaluated)
1) Was the index test or testing strategy result interpreted without
knowledge of the results of the reference standard?
Yes - if index test described as interpreted without knowledge of
reference standard result, or for prospective studies, if index test is
always conducted and interpreted prior to the reference standard
No - if index test described as interpreted in knowledge of reference
standard result
Unclear - if index test blinding is not described
2) Was the diagnostic threshold at which the test was considered
positive prespecified?
Yes - if threshold was prespecified (i.e. prior to analysing study
results)
No - if threshold was not prespecified
Unclear - if not possible to tell whether or not diagnostic threshold
was prespecified
For imaging tests only:
3) For studies reporting the accuracy of multiple diagnostic thresh-
olds (tumour characteristic or parameter) for the same index test,
was each threshold interpreted without knowledge of the results
of the others?
Yes - if thresholds were selected prospectively and each was inter-
preted by a different reader, or if study implements a retrospective
(or no) cutoff
No - if study uses prospective threshold and report states reported
by same reader
Unclear - if no mention of number of readers for each threshold
or if pre-specification of threshold not reported
N/A - multiple diagnostic thresholds not reported for the same
index test
4) For within-person comparisons (WPC) of index tests or testing
strategies (i.e. > 1 index test applied per participant), was each
index test result interpreted without knowledge of the results of
other index tests or testing strategies?
Yes - if all index tests were described as interpreted without knowl-
edge of the results of the others
No - if the index tests were described as interpreted in the knowl-
edge of the results of the others
Unclear - if it is not possible to tell whether knowledge of other
index tests could have influenced test interpretation
N/A - if only one index test was evaluated
Could the conduct or interpretation of the index test have
introduced bias?
v FOR NC and BPC STUDIES item 3) / 4) to be added
If answers to questions 1) and 2) was ‘Yes’: Risk is Low
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If answers to either questions 1) or 2) was ‘No’: Risk is High
If answers to either questions 1) or 2) was ‘Unclear’: Risk is Unclear
v FOR WPC STUDIES
If answers to all questions 1), 2) for any index test and 3) was ‘Yes’: Risk is Low
If answers to any one of questions 1) or 2) for any index test or 3) was
‘No’:
Risk is High
If answers to any one of questions 1) or 2) for any index test or 3) was
‘Unclear’:
Risk is Unclear
INDEX TEST (2) - CONCERN ABOUT APPLICABILITY
1) Were thresholds or criteria for diagnosis reported in sufficient
detail to allow replication?
This item applies equally to studies using objective and more
subjective approaches to test interpretation. For SLNB studies,
this requires description of the tracer threshold for identification
of the SLN and the histological assessment
Yes - if the criteria for diagnosis of the target disorder were reported
in sufficient detail to allow replication
No - if the criteria for diagnosis of the target disorder were not
reported in sufficient detail to allow replication
Unclear - if some but not sufficient information on criteria for
diagnosis to allow replication were provided
2) Was the test interpretation carried out by an experienced ex-
aminer?
Yes - if the test was interpreted by an experienced examiner as
defined in the review protocol
No - if the test was not interpreted by an experienced examiner
(see above)
Unclear - if the experience of the examiner(s) was not reported
in sufficient detail to judge or if examiners described as ’Expert’
with no further detail given
Is there concern that the index test, its conduct, or interpretation differ from the review question?
If answers to questions 1) and 2) was ‘Yes’: Concern is Low
If answers to questions 1) or 2) was ‘No’: Concern is High
If answers to questions 1) or 2) was ‘Unclear’: Concern is Unclear
REFERENCE STANDARD (3) - RISK OF BIAS
1) Is the reference standard likely to correctly classify the target
condition?
a) DISEASE POSITIVE - One or more of:
- Histological confirmation of metastases following lymph node
dissection (or SLNB or core biopsy for imaging studies)
- Clinical/radiological follow up to identify clinically detectable
Yes - if all disease positive participants underwent one of the listed
reference standards
No - if a final diagnosis for any disease positive participant was
reached without histopathology
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disease in a mapped nodal basin (SLNB studies)
- Clinical/radiological follow up to identify any metastases (imag-
ing studies) subsequently confirmed on histology
Unclear - if the method of final diagnosis was not reported for
any disease positive participant
b) DISEASE NEGATIVE - One or more of:
- Histological confirmation of absence of disease in a mapped
nodal basin following lymph node dissection (or following SLNB
for imaging studies)
- Clinical/radiological follow up of test negative participants
Yes - if at least 90% of disease negative participants underwent
one of the listed reference standards
No - if more than 10% of benign diagnoses were reached by
concurrent imaging test
Unclear - if the method of final diagnosis was not reported for
any participant with benign or disease negative diagnosis
2) Were the histology-based reference standard results interpreted
without knowledge of the results of the index test?
Yes - if the histopathologist was described as blinded to the index
test result
No - if the histopathologist was described as having knowledge of
the index test result
Unclear - if blinded histology interpretation was not clearly re-
ported
3) Were the reference standard results based on patient follow-up
interpreted without knowledge of the results of the index test?
Yes - if the clinician or radiologist was described as blinded to the
index test result
No - if the clinician or radiologist was described as having knowl-
edge of the index test result
Unclear - if blinded interpretation was not clearly reported
Could the reference standard, its conduct, or its interpretation
have introduced bias?
If answers to questions 1) and 2) and 3) was ‘Yes’: Risk is Low
If answers to questions 1) or 2) or 3) was ‘No’: Risk is High
If answers to questions 1) or 2) or 3) was ‘Unclear’: Risk is Unclear
REFERENCE STANDARD (3) - CONCERN ABOUT APPLICABILITY
1) Does the study use the same definition of disease positive as the
primary review question or is it possible to fully disaggregate data
such that data matching the review question can be extracted?
Yes - same definition of disease positive used, or patients can be
disaggregated and regrouped according to review definition
No - some patients cannot be disaggregated
For SLNB review - disease positive includes participants with any
nodal recurrence (not restricted to clinical recurrence in same
nodal basin)
For imaging reviews - participants with nodal versus distant re-
currences cannot be disaggregated
Unclear - definition of disease positive not clearly reported
For studies of imaging tests:
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2) The result of another imaging test (without patient follow-up to
determine later emergence of disease) was not used as a reference
standard
Yes - if imaging-based diagnosis was not used as a reference stan-
dard for any participant
No - if imaging-based diagnosis was used as a reference standard
for any participant
Unclear - if not clearly reported
3) Item on observer experience could be included?
Is there concern that the target condition as defined by the refer-
ence standard does not match the review question?
If answers to all questions 1), 2) and 3) was ‘Yes’: Concern is Low
If answers to any one of questions 1) or 2) or 3) was ‘No’: Concern is High
If answers to any one of questions 1) or 2) or 3) was ‘Unclear’: Concern is Unclear
***For teledermatology studies only:
If answers to questions 1) and 3) was ‘Yes’: Concern is Low
If answers to questions 1) or 3) was ‘No’: Concern is High
If answers to questions 1) or 3) was ‘Unclear’: Concern is Unclear
FLOW AND TIMING (4): RISK OF BIAS
1) Was there an appropriate interval between index test and ref-
erence standard?
• a) For index test positive participants, was the interval
between index test and histological reference standard <= 1
month?
Yes - if study reports <= 1 month between index and histological
reference standard
No - if study reports > 1 month between index and histological
reference standard
Unclear - if study does not report interval between index and
histological reference standard
• b) If reference standard is clinical or imaging-based follow
up of index test negative participants, was there less than 6
months between application of index test(s) and first follow-up
visit?
Yes - if study reports a follow-up visit within 6 months of appli-
cation of the index test
No - if study reports the first follow-up visit beyond 6 months of
the index test
Unclear - if study does not report timing of follow-up visits
2) Did all participants receive the same reference standard? Yes - if all participants underwent the same reference standard
No - if more than one reference standard was used
Unclear - if not clearly reported
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3) Were all participants included in the analysis? Yes - if all participants were included in the analysis
No - if some participants were excluded from the analysis
Unclear - if not clearly reported
4) For WITHIN-PERSON COMPARISONS (WPC) of index
tests:
Was the interval between application of index tests <= 1 month?
Could the participant flow have introduced bias?
Yes - if study reports <= 1 month between index tests
No - if study reports > 1 month between index tests
Unclear - if study does not report interval between index tests
v FOR NON-COMPARATIVE and BPC STUDIES
If answers to questions 1) and 2) and 3) was ‘Yes’: Risk is Low
If answers to any one of questions 1) or 2) or 3) was ‘No’: Risk is High
If answers to any one of questions 1) or 2) or 3) was ‘Unclear’: Risk is Unclear
v FOR WITHIN-PERSON COMPARATIVE STUDIES (WPC)
If answers to all questions 1), 2), 3), and 4) was ‘Yes’: Risk is Low
If answers to any one of questions 1), 2), 3), or 4) was ‘No’: Risk is High
If answers to any one of questions 1), 2), 3), or 4) was ‘Unclear’: Risk is Unclear
Appendix 5. Calculation of diagnostic accuracy statistics








True positives a b False positives Total test positive
- ve False negatives c d True negatives Total test negative
Total diseased Total nondiseased
ii) Diagnostic accuracy indices
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Sensitivity Proportion of diseased who have positive test
results
True positives / total diseased
a / (a + c)
Specificity Proportion of nondiseased who have negative
test results
True negatives / total nondiseased
d / (b + d)
Positive predictive value (PPV) Proportion with positive test result who actually
have the disease
True positives / total test positive
a / (a + b)
Negative predictive value (NPV) Proportion with negative test result who really
do not have the disease
True negatives / total test negative
d / (c + d)
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